

# Svetlana P Eckert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8955981/publications.pdf>

Version: 2024-02-01

10  
papers

154  
citations

1163117

8  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

165  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recovery of cognitive function after relapse in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 71-78.	3.0	38
2	Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. <i>CNS Drugs</i> , 2022, 36, 45-59.	5.9	21
3	Long-term drug treatment in multiple sclerosis: safety success and concerns. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1121-1142.	2.4	16
4	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. <i>Vaccines</i> , 2022, 10, 695.	4.4	16
5	Stress-full life events and multiple sclerosis: A population-based incident case-control study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 168-172.	2.0	15
6	Late onset multiple sclerosis is associated with more severe ventricle expansion. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102588.	2.0	13
7	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102653.	2.0	13
8	A decline in cognitive function should lead to a change in disease-modifying therapy – Yes. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1681-1682.	3.0	9
9	&lt;p&gt;Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives&lt;/p&gt;. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 373-384.	1.2	9
10	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 1577-1583.	2.4	4